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Abstract
Background
Whipworms and blood flukes combined infect almost one billion people in developing coun-
tries. Only a handful of anthelmintic drugs are currently available to treat these infections
effectively; there is therefore an urgent need for new generations of anthelmintic com-
pounds. Medicinal plants have presented as a viable source of new parasiticides. Ajania
nubigena, the Bhutanese daisy, has been used in Bhutanese traditional medicine for treat-
ing various diseases and our previous studies revealed that small molecules from this plant
have antimalarial properties. Encouraged by these findings, we screened four major com-
pounds isolated from A. nubigena for their anthelmintic properties.
Methodology/Principal Findings
Here we studied four major compounds derived from A. nubigena for their anthelmintic prop-
erties against the nematode whipworm Trichuris muris and the platyhelminth blood fluke
Schistosoma mansoni using the xWORM assay technique. Of four compounds tested, two
compounds—luteolin (3) and (3R,6R)-linalool oxide acetate (1)—showed dual anthelmintic
activity against S.mansoni (IC50 range = 5.8–36.9 μg/mL) and T.muris (IC50 range = 9.7–
20.4 μg/mL). Using scanning electron microscopy, we determined luteolin as the most effi-
cacious compound against both parasites and additionally was found effective against the
schistosomula, the infective stage of S.mansoni (IC50 = 13.3 μg/mL). Luteolin induced tegu-
mental damage to S.mansoni and affected the cuticle, bacillary bands and bacillary glands
of T.muris. Our in vivo assessment of luteolin (3) against T.muris infection at a single oral
dosing of 100 mg/kg, despite being significantly (27.6%) better than the untreated control
group, was markedly weaker than mebendazole (93.1%) in reducing the worm burden in
mice.
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Conclusions/Significance
Among the four compounds tested, luteolin demonstrated the best broad-spectrum activity
against two different helminths—T.muris and S.mansoni—and was effective against juve-
nile schistosomes, the stage that is refractory to the current gold standard drug, praziquan-
tel. Medicinal chemistry optimisation including cytotoxicity analysis, analogue development
and structure-activity relationship studies are warranted and could lead to the identification
of more potent chemical entities for the control of parasitic helminths of humans and
animals.
Author Summary
Schistosomiasis and trichuriasis affects millions of people worldwide and are caused by
blood flukes and whipworms, respectively. Only a handful of anthelmintic drugs exist to
treat these infections and the pipeline for the next generation of anthelmintic drugs is
sparse, precipitating the need for new drug development. In this context, medicinal plants
present a viable source of novel anthelmintic compounds. This inspired us to study the
selected naturally occurring compounds derived from a Bhutanese daisy medicinal plant,
Ajania nubigena for their anthelmintic activities. Here, using the xWORMmotility assay,
we demonstrate that two compounds, luteolin (3) and (3R,6R)-linalool oxide acetate (1),
display significant broad-spectrum anthelmintic activity against two of the most important
genera of human helminth parasites, the nematode whipworm and the platyhelminth
blood fluke. Luteolin exhibited the best activities with IC50 values of 5.8 μg/mL against
schistosomes and 9.7 μg/mL against whipworms. Using scanning electron microscopy we
showed that luteolin damages the tegument of blood flukes and induces abnormalities in
the bacillary bands/glands and cuticles of whipworms. Intriguingly, our previous study
showed that luteolin (3) was effective against multi-drug resistant Plasmodium falciparum
malaria. Due to its broad-spectrum anti-parasitic activities, luteolin (3) is a desirable drug
lead scaffold, which could be used for developing effective compounds to control and treat
numerous tropical diseases.
Introduction
TheWorld Health Organization (WHO) recognises 17 different ‘neglected tropical diseases’
(NTDs) that affect more than 1.4 billion people in 149 countries [1]. Helminth infections
caused by roundworms (nematodes) and flatworms (platyhelminths) comprise the largest
group of NTDs [2]. Whipworms (Nematoda) cause trichuriasis and infect about 800 million
people worldwide, second among the nematodes only to Ascaris infection [3]. The schistosome
blood flukes (Platyhelminthes) cause schistosomiasis, a disease that afflicts more than 240 mil-
lion individuals and kills hundreds of thousands each year [4].
A variety of approaches have been employed to combat these infections including educa-
tion, vector control, sanitation and hygiene, behavioural change and mass drug administration
(MDA) programs. Various in vitro and animal model studies have highlighted the repurposing
of existing drugs and discovery and development efforts for new drugs [2, 5] but all things con-
sidered, the pipeline for the next generation of anthelmintic drugs is sparse. Indeed, a system-
atic assessment of databases of drug regulatory authorities and the WHO, as well as clinical
trial registries, revealed that no new antiparasitic drugs have been approved during the last
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decade [6]. There are only a handful of anthelmintic drugs on the market, some of which have
unwanted side effects or achieve poor cure rates due to primary drug resistance developing in
the parasites [7–9].
For example, praziquantel, which is the sole frontline drug used in the mass treatment of
schistosomiasis, is efficacious but has many disadvantages: a) it is ineffective against juvenile
stages of the parasite, b) reduced efficacy has been reported in field studies [10], c) there is a
strong possibility that praziquantel resistance could appear if sufficient selection pressure is
applied and mass drug administration is continued [11], and d) its active (S)-enantiomer and
inactive (R)-enantiomer components remain inseparable in the production process, rendering
bulky tablets that discourages patients from taking the right doses or the complete dosing regi-
men, which could trigger the development of drug resistance [12]. Until new arsenals of safe
and effective drugs and/or vaccines are made available, helminth infections will continue to
affect the world’s most impoverished populations, causing significant morbidity and mortality
worldwide.
While new drugs can be developed synthetically, natural products—especially the medicinal
plants—have been an important pool of antiparasitic drugs. Quinine and artemisinin discov-
ered from medicinal plants continue to save the lives of millions of people worldwide. As such,
the notion of therapeutics derived from medicinal plants has re-surfaced [13]. Crude extracts
and compounds of plant origin have been demonstrated to possess broad biological activities
in in vitro and ex vivo assays and animal models of parasitic infections [14–19]. Edwards et al.
[20] showed that 7-keto-sempervirol isolated from the boxthorn from which goji berries are
harvested, Lycium chinense, was effective against Schistosoma mansoni and Fasciola hepatica.
A compound that displays such broad anti-parasitic activity against various life stages of multi-
ple parasites is highly desirable. Extracts of the Bhutanese medicinal plant from the flowering
daisy family, Ajania nubigena (Syn. Tanacetum nubigenum DC.) have been previously shown
to possess broad biological activities including antiparasitic effects against Plasmodium falcipa-
rum and antimicrobial properties [21]. It is locally known asm.khan-d.kar and has been used
in Bhutanese traditional medicine (derived from Tibetan scholarly medicine) for thousands of
years as incense and for treating an array of conditions and infections including wounds, bleed-
ing and swelling [21]. Although this plant is not specifically indicated for treating intestinal
worms, the decoction of its closely related species, Tanacetum parthenium L. (feverfew) and
Tanacetum dolichophyllum Kitam has been traditionally used by the Ladakhis Amchis (medical
system derived from Tibetan medicine and similar to Bhutanese traditional medicine) [22] and
Costa Ricans healers [23] against intestinal worms. These plants have reserves of highly aro-
matic essentials oils that have evolved to aid in plant protection and competition against plant
parasites and herbivorous insects. Chemically, these plants contain similar chemotypes includ-
ing sesquiterpenes and flavonoids [23]. Encouraged by these lead information, we have investi-
gated the anthelmintic properties of four compounds isolated from the Bhutanese A. nubigena
against two of the most important genera of human helminth parasites, the nematode whip-
worm (Trichuris) and the platyhelminth blood fluke (Schistosoma). To monitor worm viability
we used xWORM, a technique that monitors helminth motility in real time using xCELLigence
[24–25]. The advantage of using xWORM over other methods is that it enables high-through-
put screening of a large number of compounds in a fully automated, label-free manner.
Materials and Methods
Plant materials and preparation of compounds
The aerial part of wild Ajania nubigena was collected from alpine mountains (altitude range of
3600–4800 meters above sea level) of Lingzhi, Bhutan in August 2009. The collected plant
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material was air-dried and a herbarium specimen with voucher number 73 was deposited at
the herbarium collection section of Menjong Sorig Pharmaceuticals, Ministry of Health, Bhu-
tan. The air-dried plant material (2 kg) was chopped into small pieces and was repeatedly
extracted with methanol (AR/HPLC grade, 3 L over 48 h). The extract was filtered and then
concentrated using a Buchi rotary evaporator to generate a crude methanol (MeOH) extract
(58.2 g). The isolation technique was described previously [21]. MeOH extract was dissolved in
MeOH:H2O (200 mL, 1:9) and then fractionated with hexane followed by ethyl acetate to
obtain the hexane extract (28.0 g) and the ethyl acetate extract (12.5 g), respectively. Subse-
quently, essential oil (EO) extraction was performed using hydro-distillation (60°C). One kg of
dried plant material yielded 7 mL of pale green EO. The crude MeOH extract and EO were sub-
jected to extensive natural products isolation processes. Flash column chromatography packed
with Merck Kieselgel 60 PF254 and pre-coated silica plates (0.2 mm silica thickness, Merck)
were used for repeated separation and purification of compounds. UV light (short wavelength
of 254 nm, long wavelength of 366 nm) and ceric ammonium molybdate (CAM) were used for
visualization and detection of compounds on Thin Layer Chromatography (TLC) plates. Eight
compounds were isolated and characterised in total from the MeOH and EO extracts using
Infrared (IR) Spectroscopy, Mass Spectrometry (ESI-MS, HR-EI-MS), Gas Chromatography
Mass Spectrometry (GCMS), and Nuclear Magnetic Resonance (NMR-1H, 13C, gCOSY,
gNOESY, TOCSY, gHSQC and gHMBC) [21]. In this study, we have selected four major com-
pounds whose structures are produced in Fig 1: (3R,6R)-linalool oxide acetate (1), (E)-spir-
oether (2), luteolin (3) and luteolin-7-O-β-D-glucopyranoside (4).
The stock solutions of the four test compounds were prepared at the concentration of 100
mg/mL in DMSO and then subsequently diluted them with respective tissue culture media to
make 10x solutions. 20 μl of 10× drug concentration was added to 180 μl of media containing
helminths in the E-plate wells. Control worms were cultured in the presence of DMSO equiva-
lent to that used for the highest drug concentration; this group was used to determine 100%
motility. For schistosomula drug assays, stock solutions were diluted in culture media with
two-fold dilutions with in-well concentrations of (2–1000 μg/mL).
Fig 1. Structure of compounds [21]. (3R,6R)-linalool oxide acetate (1), (E)-spiroether (2), luteolin (3), luteolin-7-O-β-D-glucopyranoside (4) were derived
from A. nubigena and tested for their anthelmintic activities using xWORM. Plant photo courtesy–PW.
doi:10.1371/journal.pntd.0004908.g001
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Preparation of Schistosoma mansoni
S.mansoni cercariae were shed from infected Biomphalaria glabrata snails (Biomedical
Research Institute, MD, USA) by exposure to light at 26°C for 2 hours and used to infect 12–14
week old male BALB/c mice (120 cercariae/mouse) by abdominal penetration [26]. Adult
flukes were perfused from the mesenteries 7 weeks post-infection and then transferred to
Basch medium for culturing as previously reported [27]. To monitor the effects of drugs on S.
mansoni schistosomula, shedding of cercariae from snails and subsequent in vitro transforma-
tion to schistosomula was performed as described by Peak et al [28].
Preparation of Trichuris muris
Genetically susceptible mice (STAT6-1-) were orally infected with T.muris eggs (200 μL volume
containing ~ 200 eggs) and sacrificed after 4 weeks. Adult worms were harvested from the cae-
cum, washed with PBS/2x antibiotic/antimycotic (AA) and resuspended in 100 μl of RPMI
containing 10% foetal calf serum and AA (culture medium) then transferred to E-plates for
motility assessment using the xWORM assay.
xWORM assay
The trematocidal effects of test compounds against S.mansoni were evaluated using an xCEL-
Ligence SP system (ACEA Biosciences) as described by us [25]. Adult flukes (1 fluke per well)
were placed in triplicate for each compound into 96 well E-plates (ACEA Biosciences) contain-
ing 180 μl of culture medium and cultured overnight at 37°C with 5% CO2 to obtain a baseline
motility reading. Test compounds were added to E-plates and motility was monitored for 12–
40 hr. The inter-well spaces of E-plates were filled with 100 μL culture media. All experiments
were carried out as per manufacturer’s instructions with 15 sec read intervals using the real
time cell assay (RTCA) software (ACEA Biosciences) as described previously [24–25].
Similarly, the nematocidal effects of test compounds against T.muris were assessed using
the same xCELLigence SP system as described above. We determined the optimal culture dura-
tion and worm concentration to maximize the signal to noise ratio using the xWORM tech-
nique for the first time with T.muris. Different numbers of adult T.muris (2, 4 and 8) were
added to individual E-plate wells and motility was monitored overnight. Four worms of mixed
gender per well in a final volume of 200 μl of culture medium was determined to be optimal for
this study. The E-plates containing worms were treated with prepared concentrations of the
test compounds and were monitored using the xCELLigence SP system for 12–40 hr. Inter-well
spaces were filled with 100 μL of culture medium or PBS to prevent evaporation. Each set of
conditions was monitored in triplicate.
Determining the effects of compounds against schistosomula
The 96 well plates containing culture media were loaded with schistosomula (100 μL volume
containing ~ 100 schistosomula) in triplicate and treated with the test compounds at various
in-well concentrations of 2–1000 μg/mL. Plates were cultured at 37°C with 5% CO2 for 12–40
hr and were finally stained with trypan blue solution to assess final viability after treatment.
The stained schistosomula were observed by light microscopy, and live and dead flukes in each
well were counted manually and 50% inhibitory concentration (IC50) values were obtained.
Determination of IC50 values for test compounds
The IC50 values of test compounds were determined based on the motility index for adult
worms as described by us [25]. Briefly, motility index was calculated as the standard deviation
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(SD) over 800 data points (i.e. 4 readings per min for 200 min) of the cell index (CI) difference
from the rolling average over 20 data points (10 proceeding and preceding CI values—5 min
total). One hundred percent motility was determined from the average motility index of the
untreated wells, while 0%motility was determined from a media only well (no worms present).
The motility index averaged over 100 data points (25 min) was converted to percentage motility
and this figure was used in GraphPad Prism 6.0 to calculate dose response curves. We used a log
(test compound concentration) vs normalised response (100%–0%) formula, with variable slope
when data were sufficient or set -1 hill slope when data was limited, and automatic removal of
outliers (with default ROUT coefficient used: Q = 1.0%). IC50 values for each dose concentration
were calculated at 1 hr, 6 hr, and 12 hr post-treatment of the worms with the test compounds.
Compounds with IC50 values of higher than 100 μg/mL were considered ineffective in this study.
Statistical analysis
Statistical analyses were undertaken using GraphPad Prism 6.0. When data were sufficient to use the
variable slope analysis, the Hill Slope and the Log IC50 value were together compared for significant
differences using an extra sum-of squares F-test. For the in vivomouse experiments, 1-way ANOVA
with Holm-Sidak’s multiple comparisons test was used for determining significance p-values.
Scanning electron microscopy
Worms treated with the test compounds were prepared for scanning electron microcopy
(SEM) as follows: a) fixed in 3% gluteraldehyde in Sorensen’s buffer overnight, b) dehydrated
for 15 min in a graded ethanol series (50%, 60%, 70%, 80%, 90%, 100%), mixture of ethanol
and hexamethyldisilizane (HMDS) (1:1 ratio) and then finally with pure HMDS (100%), c) the
dehydrated worms were covered and left overnight in a fume hood to allow the HMDS to evap-
orate. Completely dried worms were placed on an aluminum stub (at least three worms from
each treatment regimen), sputtered with gold and visualized using a JEOL JSM scanning elec-
tron microscope operating at 10 kV. Each worm on a stub was scanned from head to tail to
determine if the compounds had altered its gross morphology. Digital image acquisition was
performed on the affected region of the worms using Semaphore software.
In vivo animal model studies of luteolin (3)
Four to five week-old STAT6-1- mice were grouped (each group with 9 mice) as: solvent con-
trol, positive control and luteolin (3). Each mouse was orally infected with 200 μl of PBS con-
taining approximately 200 live embyronated eggs of T.muris. These mice were housed for 4
weeks with constant access to water and pelleted food. After 4 weeks, luteolin (3) and the posi-
tive control drug (mebendazole) prepared in 1% DMSO/PBS were orally administered at a sin-
gle dose of 100 mg/kg (9 mice in total for each group) as per the protocol [29–30]. Five days
after one dose of oral treatment the mice were sacrificed, worms were harvested from the cae-
cum, and counted manually using light microscopy. The recorded numbers of worms were
averaged to find the percentage reduction in worm burden for each group of mice.
Ethics and approvals
The permit to collect medicinal plants from the park management areas around Lingzhi, Bhu-
tan was obtained from the Department of Forest, Ministry of Agriculture and Forestry in Bhu-
tan. The material transfer agreement and approval was sought from the National Biodiversity
Centre of Bhutan. MeOH extracts of the plants were transported to Australia with prior approval
from the Bhutan Agriculture and Food Regulatory Authority, University of Wollongong and
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sample inspections by Australian Quarantine & Inspection Service in 2010. The James Cook Uni-
versity (JCU) animal ethics committee approved all experimental work involving animals (Ethic
approval number A2213). Mice infected with S.mansoni and T.muris were raised in cages in the
JCU animal facility for 4–7 weeks in compliance with the Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes, 7th edition, 2007 and the Queensland Animal
Care and Protection Act 2001. Mice were kept under normal conditions at regulated temperature
(22°C) and lighting (12 hr light/dark cycle) with free access to pelleted food and water. All rea-
sonable efforts were made to minimise the suffering of the mice.
Results
The isolation and characterization of compounds from the A. nubigena plant were performed
as reported previously by us [21]. Out of eight compounds isolated from this plant, several
were reported to have antimalarial, antibacterial, antifungal and cytotoxicity activities [21].
Encouraged by the antimalarial activities, four major compounds (Fig 1): (3R,6R)-linalool
oxide acetate (1), (E)-spiroether (2), luteolin (3) and luteolin-7-O-β-D-glucopyranoside (4),
were tested for broad-spectrum anthelmintic activities against two distinct phyla of helminths,
the platyhelminth trematode blood fluke S.mansoni and the nematode whipworm T.muris.
Trematocidal activity of compounds against adult S.mansoni
Of the four compounds tested, (3R,6R)-linalool oxide acetate (1), luteolin (3) and luteolin-7-O-
β-D-glucopyranoside (4) showed anti-schistosome dose-dependent anti-schistosome effects
(Fig 2A). At the highest concentration tested (1 mg/mL) all three compounds killed flukes
within 1–12 hr. Lower drug concentrations, however, took longer to kill flukes reflected by
higher motility index values (Fig 2A).
When the IC50 values of each compound were averaged or combined (calculated for the
dose concentrations of 0.1–1000 μg/mL) for each time point (1 hr, 6 hr and 12 hr), luteolin (3)
and luteolin-7-O-β-D-glucopyranoside (4) appeared to be fast acting on worms as their IC50
values did not change significantly between the initial and final 12 hr dosing time points (Fig
2B). On the other hand, (3R,6R)-linalool oxide acetate (1) was slow-acting, showing two-fold
decreases in IC50 at each 6 hr time point. Of the compounds assessed, luteolin (3) exhibited sig-
nificantly better trematocidal activity at both 6 hr and 12 hr time points with IC50 values of
4.6 μg/mL and 5.8 μg/mL, respectively.
Effects of compounds against schistosomula of S.mansoni
The compounds that were active against adult S.mansoni were also tested against the intra-
mammalian larval stage, the schistosomulum. Monitoring of schistosomula survival in the
presence of different drug concentration using Trypan blue exclusion showed that luteolin (3)
started to show lethal effects at the lowest dilution of 3.91 μg/mL and achieved 98–100% killing
at the dilution of 31.3 μg/mL. (3R,6R)-linalool oxide acetate (1) however started to show lethal
effects at a concentration of 125 μg/mL and only achieved about 43% killing at the maximum
dose tested of 250 μg/mL. Schistosomula treated with 1% DMSO alone (solvent control) had
100% survival as measured by Trypan blue exclusion. A dose response curve of schistosomula
survival after treatment with luteolin (3) revealed an IC50 of 13.3 μg/ml (Fig 3B).
Effects of luteolin (3) on the morphology of adult S.mansoni
Luteolin (3) demonstrated the best anthelmintic activity when motility was assessed using
xWORM. The effect of this compound and praziquantel on adult fluke morphology at
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4–20 μg/mL concentration, with particular emphasis on the tegument, was assessed by SEM.
Adult flukes treated with praziquantel adopted a tightly coiled appearance due to contraction.
Both male and female flukes treated with luteolin (3) were contracted and coiled compared to
control flukes cultured in 1% DMSO in media, but not as tightly coiled as praziquantel-treated
parasites (Fig 4A–4F).
Observation of fluke teguments by SEM under high magnification revealed that the tegu-
ment of DMSO-treated flukes displayed numerous tubercles, with well-formed spines in the
males (Fig 5A) and clearly defined surface grooves with sensory papillae in females (Fig 5B),
and oral suckers with clearly defined pits containing sharp spines (Fig 5C). Flukes treated with
praziquantel (Fig 5D–5F) and luteolin (3) (Fig 5G–5I) exhibited severe morphological alter-
ations of the tegument.
At the lowest concentration tested of 4 μg/mL we observed clear tegumental damage
induced by luteolin (3) (Fig 5G–5I), similar to that induced by praziquantel (Fig 5D–5F).
While male flukes (Fig 5G) suffered partial loss of pits and their encased spines, female flukes
(Fig 5E) showed surface erosion, constriction of grooves, bursting of small sensory papillae and
formation of holes on the tegument. At higher concentrations of 20–1000 μg/mL, luteolin (3)
and praziquantel completely destroyed the body surfaces and exhibited erosion of tubercles,
oral and ventral suckers (S1 Fig).
Fig 2. In vitro anti-schistosome activities of four compounds against adult S.mansoni. A) Motility index dose
response curve of worms at the 12 hr time point when treated with (3R,6R)-linalool oxide acetate (1), (E)-spiroether (2),
luteolin (3), luteolin-7-O-β-D-glucopyranoside (4) (abbreviated as Com-1, Com-2, Com-3 and Com-4) at different
concentrations (0.1–1000 μg/mL). Motility index was calculated as the standard deviation (SD) over 800 data points
(i.e. 4 readings per min for 200 min) of the cell index (CI) difference from the rolling average over 20 data points (10
proceeding and preceding CI values—5 min total). B) 50% inhibitory concentration (IC50) curves over time. Error bars
represent 95% confidence intervals of nonlinear curve fit. The curves were marginally shifted on the x-axis to aid
viewing. These figures represent the data from three independent studies.
doi:10.1371/journal.pntd.0004908.g002
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Nematocidal activities of compounds against adult T.muris
Prior to testing the nematocidal effects of (3R,6R)-linalool oxide acetate (1), (E)-spiroether (2),
luteolin (3) and luteolin-7-O-β-D-glucopyranoside (4), we standardized the culturing condi-
tions of adult T.muris for the xWORM assay. E-plate wells containing four adult worms (both
males and females) yielded optimal motility signals (S2 Fig), and was the condition selected for
subsequent anthelmintic screening of the test compounds. (3R,6R)-linalool oxide acetate (1)
and luteolin (3) showed the best anti-Trichuris activity with IC50 values of 20.4 μg/mL and
9.7 μg/mL, respectively, calculated on cell motility index at the 12 hr time point (Fig 6A).
The IC50 values of the four compounds tested here were obtained using xWORM and calcu-
lated at 1 hr, 6 hr and 12 hr time points (Fig 6B). Luteolin (3) was the most efficacious drug in
terms of reduced motility of T.muris, exhibiting the lowest or equally low IC50 values at all
time points and a final 12 hr value of 9.7 μg/mL.
Effects of luteolin (3) on the morphology of adult T.muris
Based on the efficacy of luteolin (3) at reducing Trichurismotility, we examined the morpho-
logical changes in the cuticle induced by this compound using the SEM protocols described by
Stepek et al [30] and Tritten et al [31] specific to T.muris. Live adult T.muris (mixed sexes)
were treated for 48 hr with luteolin (3) or mebendazole at dose concentrations of 200–1000 μg/
mL. Morphological changes were observed towards the anterior end of the worms in the form
of partially damaged bacillary band/glands and adjacent cuticle. The bacillary band is a
Fig 3. Effect of compounds on the survival of schistosomula. A) Images (20x) of wells containing
schistosomula that were treated with linalool oxide acetate (1) and luteolin (3) (abbreviated as Com-1 and Com-3)
at the maximum concentration tested of 250 μg/mL and stained with trypan blue. Deep blue staining signifies a
dead parasite. B) The effect of (3R,6R)-linalool oxide acetate (1) and luteolin (3) (abbreviated as Com-1 and Com-
3) on schistosomula mortality observed at two-fold dilutions (250–1.9 μg/mL). The data was generated from
triplicate samples obtained from two independent studies.
doi:10.1371/journal.pntd.0004908.g003
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specialized row of longitudinal cells of some nematodes consisting of glandular and non-glan-
dular cells. These bands host the glands. Worms treated with DMSO/media (solvent control)
alone had a moderately coiled appearance with a smooth cuticle displaying knitted parallel seg-
mental joins and minimal shrinkage of bands (Fig 7A–7C) in comparison to the groups treated
with mebendazole (Fig 7D–7F) and luteolin (3) (Fig 7G–7I). At higher magnification we
observed that the luteolin-treated worms exhibited blister-like formations on the surface of the
cuticle, swelling and loosening of cuticle seams/grooves near the bacillary glands (Fig 7I).
These morphological changes were similar to that of the mebendazole-treated worms (Fig 7F).
Fig 4. Effects of luteolin (3) and praziquantel on the morphology of adult S.mansoni at 4–20 μg/mL
concentration visualized using scanning electron microscopy. A, C and E showmale flukes. B, D and F
depict female flukes. (A, B) Flukes in DMSO/media control. (C, D) Flukes treated with praziquantel (tightly
coiled). (E, F) Flukes treated with luteolin (3) (moderately coiled). Three separate wells (with 3–5 adult flukes
per well) were treated with different doses of test samples as above and each of them was examined under
SEM.
doi:10.1371/journal.pntd.0004908.g004
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Anti-Trichuris effect of luteolin (3) in mice infected with T.muris
Based on the significant in vitro nematocidal activity demonstrated by luteolin (3), this com-
pound was further assessed for its anti-Trichuris effect in vivo using a mouse model of T.muris
infection [29–31]. Four weeks post-infection with T.muris eggs, mice were administered with a
single 100 mg/kg oral dose of luteolin (3). When mice were sacrificed 5 days later we observed
that a single treatment of this compound resulted in a 27.6% reduction in worm burdens (249
worms); luteolin (3)–treated mice = 651 worms; DMSO-treated mice = 900 worms;
P = 0.0087) (Fig 8). The positive control drug, mebendazole, reduced worm burdens by 93.1%
(mebendazole treated mice = 50 worms). The activity of luteolin (3) against T.muris, despite
being significantly better than the untreated control group, was markedly weaker than meben-
dazole in the mouse model. Mice treated with luteolin (3) did not show signs of toxicity at any
of the concentrations tested.
Discussion
Globally, helminth infections caused by roundworms (nematodes) and flatworms (platyhel-
minths) comprise the largest group of NTDs [2]. Schistosomiasis (caused by the platyhelminth
blood flukes) and trichuriasis (caused by the nematode whipworms) affect about 240 million
and 800 million people, respectively [3–4]. While schistosomiasis is transmitted through
infected snails and water, trichuriasis is transmitted through soil and is therefore referred to as
a soil-transmitted helminth infections (STHI). The STHI are among the most common
Fig 5. Scanning electronmicrographs of S.mansoni adult fluke teguments after treatment with 4 μg/mL
concentration of luteolin (3) and praziquantel. A, B and C represent flukes treated with solvent (1% DMSO in culture
media). A) Male tegument with well defined tubercles. B) Female tegument with clearly defined grooves and sensory
papillae. C) Oral sucker with well formed pits containing spines. D, E and F represent flukes treated with praziquantel.
D) Male tegument with damaged tubercles and spines. E) Female tegument with damaged papillae and swollen
grooves. F) Oral suckers with eroded pits and detached spines. G, H and I represent flukes treated with luteolin (3). G)
Male tegument with destroyed tubercles and holes. H) Female tegument with burst sensory papillae and holes. I) Oral
suckers with partially eroded pits. Arrows in panels highlight treatment effects described in results text. All images at
×4000 magnification and 1 μm are scale bars shown.
doi:10.1371/journal.pntd.0004908.g005
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infections worldwide and affect the poorest and most deprived communities where sanitation
is poor. Sole reliance on praziquantel for schistosomiasis, and only a very small number of
drugs (some with poor cure rates) for STHI, has precipitated the need for new anthelmintic
drugs to treat parasites that infect both humans and animals [7]. In this context, medicinal
plants present a viable source of novel anthelmintic compounds. Indeed, many anti-parasitic
drugs including quinine, chloroquine, artemisinin and atovaquone were originally purified
from plants. Our initial study, involving the crude CHCl3 extract of A. nubigena (syn. Tanace-
tum nubigenum DC.) and its compounds luteolin and luteolin-7-O-β-D-glucopyranoside,
showed significant antiparasitic activities against the multidrug resistant K1CB1 strain and
chloroquine sensitive TM4/8.2 strain of Plasmodium falciparum [16, 21]. Interestingly, this
plant and its close relatives have been used in the ethnomedicines for treating arrays of disor-
ders including wound, bleeding and worm infection [16, 21–23].
In this study, we have demonstrated that compounds linalool oxide acetate (1) and luteolin
(3) had significant trematocidal activity against S.mansoni and nematocidal activity against T.
muris. These compounds are simple small secondary plant metabolites belonging to the ter-
penes and flavonoids. Luteolin (3) was the most active compound against both parasites with
IC50 values of 5.8 μg/mL against S.mansoni and 9.7 μg/mL against T.muris calculated at the 12
hr time point. It also effectively killed schistosomula with an IC50 value of 13.3 μg/mL. Intrigu-
ingly, this same compound has been shown to have significant anti-malarial activity against P.
falciparum TM4/8.2 (chloroquine-antifolate sensitive strain) and K1CB1 (multidrug resistant
Fig 6. Anti-Trichuris activity of compounds (1–4) on adult T.muris. A) Motility index dose response curve of worms
at the 12 hr time point when treated with (3R,6R)-linalool oxide acetate (1), (E)-spiroether (2), luteolin (3) and luteolin-7-
O-β-D-glucopyranoside (4) (abbreviated as Com-1, Com-2, Com-3 and Com-4) at different concentrations. Motility
index was calculated as the standard deviation (SD) over 800 data points (i.e. 4 readings per min for 200 min) of the
cell index (CI) difference from the rolling average over 20 data points (10 proceeding and preceding CI values—5 min
total). B) Combined IC50 values of these four compounds calculated for three different doses at 1 hr, 6 hr, and 12 hr
time points. Error bars represent 95% confidence intervals of nonlinear curve fit. The curves were marginally shifted on
the x-axis to aid viewing. These figures represent the data from three independent studies.
doi:10.1371/journal.pntd.0004908.g006
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strain) [21]. New anti-parasitic drugs require excellent safety and therapeutic profiles, should
exhibit broad spectrum activity against different types of infections, and also display significant
activity against different developmental stages of parasites. Current anthelmintic drugs are gen-
erally effective at treating single stages of target helminths. For example, praziquantel is effec-
tive against adult stage schistosomes but not schistosomula/cercariae. Therefore, finding a
broad-spectrum drug that could treat multiple diseases or multiple life stages is desirable when
treating large populations in resource-poor settings. Luteolin (3) met these criteria in that it
has anti-malarial [21], anti-fluke and anti-whipworm properties. In addition, this compound
was effective in killing schistosomula, the stage of S.mansoni that is unaffected by
praziquantel.
While our findings do not specifically address the mechanism of action of these anthelmin-
tic compounds, we showed that luteolin (3) is capable of damaging the outer surface mem-
branes of the parasites–the fluke tegument and the nematode cuticle and associated glandular
structures, and worms adopted a coiled state of paralysis. Previous studies on S.mansoni have
demonstrated that the tegument plays essential roles in many processes at the host-parasite
interface, and numerous molecular pathways that are represented at the host-parasite bound-
ary are anti-parasitic drug targets [5, 32]. SEM has been used to demonstrate the mechanisms
of many anti-parasitic drugs, including oxamniquine, praziquantel, mefloquine, mebendazole
and artemisinin [20, 32–39]. Schistosomes treated with these drugs displayed vacuolization or
bubble-like-lesions, surface erosion, destruction of tubercles and tissues, loss of sensory
Fig 7. Effects of luteolin (3) andmebendazole on the cuticle of adult T.muris. A) Normal appearance of control
worms cultured in 1% DMSO/media (x100) and at higher magnification focusing on the cuticle (B) and bacillary gland
(C), respectively. D) Shrinkage of the anterior regions of worms after treatment with mebendazole and damage to the
cuticle (E) and bacillary glands (F) were observed at higher magnification. G) Shrinkage of the anterior regions of
worms after treatment with luteolin (3) and damage to the cuticle (H) and swelling of bacillary glands (I) observed at
higher magnification. Red arrows in all panels highlight treatment damage described in results text.
doi:10.1371/journal.pntd.0004908.g007
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papillae, and pore formation leading to death. SEM has also been used to reveal cuticular damage
in nematodes, particularly for the benzimidazole class of drugs [40–41]. Stepek et al [30] and
Tritten et al [31] first used the plant extracts and nitazoxanide to demonstrate the mechanisms of
the antiparasitic action against T.muris. These same morphological changes were observed in
adult S.mansoni and T.muris that were treated with luteolin (3), suggesting that the mechanism
of action is similar to at least some of the existing anthelmintic drugs. For T.muris, luteolin (3)
and mebendazole mainly affected the anterior bacillary band and surrounding glands. The
Fig 8. Effects of luteolin (3) andmebendazole on T.muris burden in mice. The graph represents the
percentage of worms recovered from the STAT6-1-mice five days after a single oral dose of luteolin (3)
(27.1% reduction with p-value of 0.0087) and the positive control drug, mebendazole (93.1% reduction with
p-value of 0.0005). The p-values were determined by one-way ANOVA Holm-Sidak’s multiple comparisons
test. Each experimental group consisted of nine mice.
doi:10.1371/journal.pntd.0004908.g008
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anterior ventrolateral face of the worm contain the glandular pores, bacillary band sensory cells
and glands, and the stichosome cells which helps in the formation of the syncytial feeding site in
the host, and plays an important role in the excretion of digestive enzymes, pre-digestion and
nutrient uptake in Trichuris [42–45].
Luteolin (3), with a LogP value of 2.6, meets the Lipinski rule of 5 criterion for drug-likeness
[46]. Generally, compounds with LogP values in the range of 2–3 are more likely to diffuse/per-
meate through the cell membrane of an organism, and therefore enabling them to interact with
target receptors. There was no structural similarity between our active compounds and the cur-
rently used anthelmintic drugs, which suggest that compounds that damage the worm surface
do not necessarily have similar structural scaffolds. It should be noted that our in vivo assess-
ment of luteolin (3) against T.muris infection at a single oral dosing of 100 mg/kg, despite
being significantly (27.6%) better than the untreated control group, was markedly weaker than
mebendazole (93.1%) in reducing the worm burden in mice. Moreover, the mice showed no
signs of ill health, suggesting that luteolin (3) is not overtly toxic and allows future studies to
explore the efficacy of multiple treatments. We did not assess in vivo efficacy of luteolin (3)
against S.mansoni in the mouse model. Future work will entail synthesis of luteolin and its
derivatised compounds in a thorough in vivo assessment of efficacy in mouse models of schis-
tosomiasis and trichuriasis, as well as other soil-transmitted helminth infections.
Supporting Information
S1 Fig. SEM images of damaged tubercles, oral and ventral suckers (anterior parts) of S.
mansoni (male) when treated with luteolin (3) and praziquantel at a dose concentrations of
20–1000 μg/mL. Praziquantel treated groups (A and C). Luteolin treated groups (C and D).
(TIFF)
S2 Fig. Motility signals of T.muris (mixed male and female) obtained by xCELLigence with
2–16 worms per well. A) depicts the Motility Index of 2–16 worms per well over 12 hours. B)
depicts the average blanked Motility Index of 2–16 worms per well over 12 hours with standard
deviation error bars (generated from data shown in A). Four worms per well was determined
as optimal as the motility index signal was the most stable over time, with lowest variation.
(TIF)
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